KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.
| 10.7 | |
| 11.2 | |
| - | |
| 11.2 | |
| 10.7 | |
| 6.9-20.2 | |
| 468 M | |
| 43 216 K | |
| 3 824 K | |
| -0.66 | |
| 0.889 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
KalVista Pharmaceuticals Inc (NASDAQ:KALV), a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant un...
Edward Feener, Chief Scientific Officer of KalVista Pharmaceuticals Inc (NASDAQ:KALV), executed a sale of 17,321 shares in the company on January 9, 2024, according to a recent SEC Filing. KalVista Ph...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
